At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
Letrozole; Avastin +1 moredrug
Likely dose
Letrozole; Avastin 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Open Label Trial of Pre-operative (Neoadjuvant)Letrozole (Femara) vs. Letrozole in Combination With Avastin in Post Menopausal Women With Newly Diagnosed Operable Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Letrozole (Femara) and Letrozole; Avastin for Breast Cancer and 2 related conditions. Completed, enrolled 75 participants across 7 sites.
Detailed Summary
This purpose of this trial is to show that the combination of Avastin and hormone therapy should be more effective than hormone therapy alone for the treatment of breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Cancer of the Breast, Breast Neoplasm
CountriesUnited States
CollaboratorsGenentech, Inc., Breast Cancer Research Foundation
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2007
Enrollment StartOct 2007
Primary CompletionMar 2022
Study CompletionMar 2022
TodayJul 2026
First PostedSep 18, 2007
Enrollment StartOct 8, 2007
Primary CompletionMar 1, 2022
Study CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 14.4 yearsPosted 18.8 years ago
Interventions
Letrozole (Femara)other
Letrozole 2.5 mg PO a day for 24 weeks
Letrozole; Avastindrug
Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks